Cullinan Therapeutics Stock Forecast
NASDAQ: CGEMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CGEM analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$33.45+116.36%
- Strong buy 1
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Cullinan Therapeutics (2026-10-08), 12 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $33.45, with a high estimate of $42.00 and a low estimate of $23.00. The average target implies upside of 116.4% from the current price of $15.46.
The spread between the highest and lowest targets is 82.6%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CGEM.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 8% |
| Buy | 11 | 92% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $23.00 | +48.77% |
| Average target | $33.45 | +116.36% |
| High target | $42.00 | +171.67% |